Progression After Cancer Immunotherapy in Advanced NSCLC

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

New Psoriasis Treatments

Treatment Algorithms in Melanoma: Past, Present, and Future

Unraveling Clinical Developments in NASH

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

New Standards of Care in ALK-Translocated Advanced NSCLC

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Therapeutic Approaches to the Management of EDS in OSA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

When Is Biologic Therapy Appropriate for HS?

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Talking With Your Patients About Excessive Sweating

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

How to Select Therapy in Relapsed/Refractory CLL

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Progression After Cancer Immunotherapy in Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Patterns of Progression

Considerations for Management of Progressive Disease

Patient Case #1

Second-Line Treatment Options

The Treatment Option of Clinical Trials

Patient Case #1 (cont)

Patient Case #2

Third-Line Treatment Options

Tips for Remaining Current With Data

Concluding Remarks

Abbreviations